of risk factors, and smoking status. Patients with ≥4 risk factors account for 71.7% of current glycemic control group, while this value reached 84.3% in the uncontrolled group (P < 0.0001). CONCLUSIONS: In one out of seven patients with DM2 and poor glycemic control, none action to intensify treatment has been taken during the past 2 years. Patients without current glycemic control have more than two times higher clinical inertia than the controlled ones. Intensifi cation of treatment is twice as common in patients currently uncontrolled (85.1% vs. 44.9%).
1
Bristol-Myers Squibb, Mexico City, Mexico; 2 AstraZeneca, Edo. de Méx., Mexico; 3 Bristol-Myers Squibb, Wallingford, CT, USA OBJECTIVES: Diabetes affects approximately 8 million people in Mexico and is the fi rst cause of death in the country. Ninety percent of all diabetes is classifi ed as type II diabetes (T2DM). Saxagliptin, a DPP4 inhibitor, is one of a class of drugs orally administered for treatment of T2DM. Petroleos Mexicanos (PEMEX) health-care system covers approximately 43,977 patients diagnosed with T2DM. The objectives of this study are to: 1) analyze the current utilization and expenditure for oral antidiabetics (OADs) by PEMEX; and 2) evaluate the budget impact of saxagliptin for treatment of T2DM population. METHODS: An MS Excel-based budget impact model of the total population diagnosed with T2DM in PEMEX was used. OAD usage was based on the total amount purchased, by the Institution in 2009. The prices of medications were taken from the published price listing by PEMEX (2009). The following OAD medications were included in the analysis: pioglitazone, rosiglitazone, vildagliptin, and saxagliptin. Pharmaceutical expenses of OADs were considered excluding other medical costs. The time horizon was 3 years and the assumptions of the model including market dynamics were estimated by Bristol Myers Squibb. The budget impact is reported in terms of additional annual total costs. Results are presented in US dollars with an exchange rate of $13.4 MXN. RESULTS: The usage of saxagliptin in PEMEX represents savings to the institution of US$56,132 for the fi rst year of use, with increases in savings for year two and year three US$102,910 and US$154,441 respectively. The impact of saxagliption on the budget was primarily driven by the gradual substitution of pioglitazone, rosiglitazone, and vildagliptin with saxagliptin over the 3-year of analysis. CONCLUSIONS: The budget impact of adding saxagliptin as a treatment option for T2DM patients reveals that the accumulated savings for PEMEX for the estimated timeframe is around US$ 313,485. The present model was aimed to demonstrate the annual cost of the smoking-related diseases in patients with type 2 diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD), and to establish the budget that would be saved with varenicline (nicotinic receptor partial agonist) reimbursement by the government. METHODS: The model was carried out in two contexts; the costs of the smoking-related diseases and exacerbations in patients with type 2 DM and COPD were estimated in smoking conditions, and varenicline use. The model was constructed on a total of 900,000 type 2 DM patients and 106,410 COPD patients by assuming approximately 3.8 million type 2 DM patients and 2.0 million COPD patients in Turkey of which 23% and 48% were considered to be smokers, respectively. RESULTS: According to the model, the ratio of patients willing to quit smoking was estimated as 35% in type 2 DM group and 54% in COPD group. Of those, 20% (n = 63,000) type 2 DM patients and 30% (n = 17,238) COPD patients were assessed to use varenicline. The annual cost of the smoking-related diseases and exacerbations was calculated as 72.40 million USD according to the 43,341 events; the unit direct costs for myocardial infarcts, stroke, and congestive heart failure were calculated as US$2,523.55, US$1,930.70, and US$1,412.33, respectively, in type 2 DM patients, whereas it was US$1,567.55 in COPD patients. After varenicline use, the government would save US$9.47 million per year by 5608 preventable events. Moreover, the annual cost of varenicline was estimated to be US$23.46 million for 80,238 patients. Accordingly, the total cost of the smoking-related diseases and exacerbations would be US$13.99 million for the fi rst year. CONCLUSIONS: Varenicline reimbursement decreases the annual cost of the smoking-related diseases and exacerbations in patients with type 2 DM and COPD.
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PDB21 COMPARISON OF COSTS OF THE INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS WITH INSULIN GLARGINE AND INSULIN DETEMIR
Álvarez Guisasola F 1 , Mauricio Puente D 2 , Garcia Coscolin T 3 , Rubio Terres C 4 1 Center of Health La Calzada, Gijón, Asturias, Spain; 2 Vilanovaxs Arnau Hospital, Lleida, Spain; 3 Sanofi -Aventis, Madrid, Spain; 4 Health Value, Madrid, Spain OBJECTIVES: Large published data suggested that some patients initiating with the recommended once-daily detemir administration require twice-daily dosing to optimize blood glucose control; therefore, the clinical outcome in this selected population was tested in a randomized controlled trial. The objective of this study is to compare the costs of two treatments of type 2 diabetes mellitus (DM2): Insulin glargine (glargine) and insulin detemir (detemir) in patients with DM2 not controlled with OADs. METHODS: A costs analysis of the insulin treatment was carried out with National Health System perspective. Costs with glargine or detemir linked to DM2 patients were calculated according to the administered doses in a clinical trial of 24 weeks of duration, which included 964 insulin-naive patients, with a DM2 average duration of 10 years and average HbA1c = 8.7%. For both insulin, started dose was 0, 2 U/kg. The administration of a daily dose of glargine and two daily doses of detemir led to similar average levels of glycosylated hemoglobin (−1.46 ± 1.09 and −1.54 ± 1.11 %; P = 0.149). However, patients treated with glargine needed significantly minor insulin than those treated with detemir (43.5 vs. 76.5 U, P < 0.001).
RESULTS:
The application of this model would be translated in minor daily costs for glargine and concretely its use would suppose an annual cost of c814.52 opposite to the c1461.5 of detemir. In consequence, utilization of glargine instead of detemir would be associated with an annual saving of c647.13 for patient with DM2, which supposes a saving of 44.2% with glargine opposite to detemir. CONCLUSIONS: According to the present model, in the above mentioned population, insulin glargine is a treatment of the DM2 associated with minor costs than insulin detemir. The objective of this study is to determine the potential differences in the economical impact for the National Health System (NHS) in Spain of using different glucometric systems for self-monitoring blood glucose (SMBG) in patients with type II diabetes mellitus (DM II). METHODS: An economic model was built based on three information sources: 1) literature review; 2) costs databases; and 3) expert opinion. Six different glucometers were analyzed according to their codifi cation characteristics and their corresponding strips package characteristics, leading to four different system possibilities: 1) autocoded/individual strip package; 2) manually coded/ individual strip package; and 3) autocoded/ collective strip package; and 4) manually coded/collective strip package. The perspective was that of the NHS. RESULTS: With more than 2 million people suffering from DM II in Spain, we calculated the impact of glucometer miscoding relating it to cardiovascular episodes and glucose disorders occurred. Also, collective strip package implied, due to shorter time of strip stability after its opening, considerable strip waste especially in those patients with low frequency of SMBG recommendation. Results show that autocoded glucometers which have individual package for strips safe c5 million (10%) versus those manually coded and having individual strip package in diabetic patients' management to the NHS; versus those autocoded but with collective strip package, savings rise to c15 million (24%) and versus those manually coded and with collective package the amount of saving is of c22 million (31%). The one-way sensitivity analysis performed with the most relevant variables confi rmed this tendency. CONCLUSIONS: Glucometric systems not requiring patient intervention for coding and with individual strip package minimize the total cost of SMBG of type II diabetic patients in Spain.
PDB22 COST STUDY OF SELF-MONITORING BLOOD GLUCOSE THROUGH GLUCOMETERS IN PATIENTS WITH DIABETES MELLITUS II IN SPAIN
PDB23 COST ANALYSIS FOR THE TREATMENT OF DIABETES MELLITUS IN DIFFERENT HEALTH SECTORS OF HEALTH-CARE SYSTEM OF PAKISTAN
Malik M, Hussain A, Khan J Hamdard University, Islamabad, Punjab, Pakistan OBJECTIVES: Despite the efforts made worldwide, data regarding the cost of care in Pakistan are scarce. This study was aimed at assessing the direct costs incurred in the treatment of diabetes and its variation among government, semi-government, and private sectors of Islamabad, Pakistan. METHODS: It was a comparative cross-sectional study in which data was collected from patients by conveniently sampling. The direct cost of treatment of diabetes was determined in terms of variables consultation fee, cost of medicine, travelling cost, fees for laboratory test for glucose monitoring, cost of home blood glucose monitoring device, and cost of strips used for home blood glucose monitoring. RESULTS: The annual mean direct cost for government, semigovernment, and private sectors were Rs. 6481.73, Rs. 9785.25 and Rs. 27790.31, respectively, while the monthly mean directs costs were Rs. 540.14, Rs. 815.43, and Rs. 2315.85, respectively. The total direct cost of treatment of diabetes per month for all health facilities was Rs. 986.61. It was found from the analysis that the mean costs for individual variables were highest in the private sector as compared to semi-government and government sector. The consultation fee charged by the private sector is much higher than the other two sectors. CONCLUSIONS: The private sector of Pakistan is incurring more cost for the treatment of diabetes mellitus. This difference in cost among health sectors is a burden on the economic status of the country. Moreover, untreated diabetes or comorbidities increase the overall treatment cost and this can affect the affordability of the patient.
